TrialCancer research and treatment2020

PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane-Based Neoadjuvant Chemotherapy.

Sanxing Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.